Company intelligence / Profile preview
Anti-Microbial Savior BioteQ
- Ownership
- Private
- Development stage
- Other
Overview
Anti-Microbial Savior BioteQ (AMS BioteQ) is a Taiwan-based biotechnology company focused on developing innovative anti-microbial and wound-healing solutions. The company utilizes its proprietary Medi-Plus platform to develop natural-based compounds with broad-spectrum efficacy against viruses and bacteria, including COVID-19 and antibiotic-resistant strains. Their lead research focuses on the S-SMRi (Surface-Specific Molecular Recognition and Inhibition) technology to prevent viral entry into host cells. Beyond therapeutics, AMS BioteQ is expanding into medical devices and functional materials for infection control.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small moleculeNatural productBiologic
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Anti-Microbial Savior BioteQ.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-Microbial Savior BioteQ.